Kymera to present KT-621 atopic dermatitis trial data at dermatology meeting
Tweet Send to a Friend
Kymera Therapeutics Inc. (NASDAQ: KYMR) will present Phase 1b clinical trial data for its experimental drug KT-621 in atopic dermatitis ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
